Medication info
Sitagliptin/Metformin Duo Tablet 50/850 mg

Sitagliptin/Metformin Duo Tablet 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300857 · Approved 2023.03.13 · Insurance code 648508200

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient’s blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Studies evaluating the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes. Sitagliptin and Metformin work together to effectively lower blood sugar and assist in diet and exercise therapy. Therefore, this medication is helpful in the treatment of type 2 diabetes.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient’s blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Studies evaluating the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Precautions

This medication contains Sitagliptin and Metformin and is primarily used for blood sugar control in patients with type 2 diabetes. Firstly, serious allergic reactions may occur during the use of this medication; if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a healthcare professional. Additionally, pancreatitis, which is inflammation of the pancreas, can rarely occur as a serious side effect; if severe abdominal pain, vomiting, or significant discomfort occurs, visit the hospital immediately. The Metformin component in this medication can cause a rare but fatal complication called lactic acidosis; if sudden muscle pain, weakness, difficulty breathing, or abdominal pain occurs, discontinue use immediately and seek emergency treatment. Patients with impaired kidney function or conditions that affect kidney function such as severe infections, dehydration, congestive heart failure, or acute myocardial infarction should not take this medication. Furthermore, pregnant women, women who may become pregnant, and nursing mothers should not take this medication. Patients with irregular or insufficient food intake, those who engage in vigorous exercise frequently, and those allergic to certain colorants should take this medication with caution. Hypoglycemic symptoms may occur during treatment; if symptoms such as dizziness, cold sweat, extreme hunger, or trembling appear, sugar should be taken immediately. The risk of hypoglycemia is higher, particularly when taking this medication with other hypoglycemic agents such as insulin or sulfonylureas. Before surgery or radiographic examinations using contrast agents, inform healthcare providers about the use of this medication, and if necessary, temporarily discontinue use. Regular tests of liver or kidney function should be conducted, and if abnormalities are found, dosage adjustments or discontinuation may be necessary. Excessive alcohol consumption should be avoided while using this medication, as alcohol intake may increase the risk of lactic acidosis. Finally, if new symptoms or adverse reactions occur while taking this medication, it is important to immediately inform and consult with a healthcare provider.

Side effects

  • Severe hypersensitivity reaction
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
Show 23 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • itching
  • weight loss
  • dermatitis
  • loss of appetite

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering and kept at room temperature between 1 to 30 degrees Celsius. Proper temperature and environment maintenance will help preserve the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.